Breaking News Instant updates and real-time market news.

GOOG

Alphabet

$2,584.63 /

+48.885 (+1.93%)

, GOOGL

Alphabet Class A

$2,582.05 /

+40.4 (+1.59%)

06:46
01/27/22
01/27
06:46
01/27/22
06:46

Verily, GSK reach milestone in RA neuromodulation, first patient implant

Five years ago, Verily, a subsidiary of Alphabet (GOOG;GOOGL), and GlaxoSmithKline (GSK) announced they were forming a new research and development-focused company, Galvani Bioelectronics. This new venture would be dedicated to treating chronic conditions, including Rheumatoid Arthritis, RA, through targeted neuromodulation therapies. Yesterday, the companies announced the successful implantation of the first-ever investigational treatment for RA through stimulation of the splenic nerve in a patient. The Galvani neurostimulator is designed to be implanted in a minimally invasive outpatient procedure. After implantation the patient and their care provider are then able to control, monitor, and charge the device as needed to ensure continued potential efficacy. In November 2021, a team of laparoscopic surgeons successfully completed the first implantation of a Galvani device in a patient. Over the last month, therapy was initiated as part of a small clinical study at the NHS Greater Glasgow and Clyde Health Board. At the same time, Galvani has also kicked off a larger U.S.-based study under approval from the FDA. This study will assess the safety and effectiveness of the Galvani platform in the RA patient population.

GOOG

Alphabet

$2,584.63 /

+48.885 (+1.93%)

GOOGL

Alphabet Class A

$2,582.05 /

+40.4 (+1.59%)

GSK

GlaxoSmithKline

$44.18 /

-0.18 (-0.41%)

  • 01

    Feb

  • 01

    Feb

  • 09

    Feb

  • 27

    Mar

  • 03

    Jun

OTHER BREAKING NEWS FROM THE FLY

Downgrade
JBG Smith downgraded to Peer Perform from Outperform at Wolfe Research » 06:33
05/23/22
05/23
06:33
05/23/22
06:33
JBGS

JBG Smith Properties

$24.97 /

+0.045 (+0.18%)

Wolfe Research analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JBGS JBG Smith Properties
$24.97 /

+0.045 (+0.18%)

JBGS JBG Smith Properties
$24.97 /

+0.045 (+0.18%)

03/03/22 Evercore ISI
Evercore ISI shakes up Office REIT ratings with one upgrade, two downgrades
07/12/21 BMO Capital
JBG Smith Properties initiated with an Outperform at BMO Capital
Hot Stocks
ImmunoGen's BLA for mirvetuximab soravtansine in ovarian cancer accepted by FDA » 06:32
05/23/22
05/23
06:32
05/23/22
06:32
IMGN

ImmunoGen

$3.58 /

+0.055 (+1.56%)

ImmunoGen announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IMGN ImmunoGen
$3.58 /

+0.055 (+1.56%)

IMGN ImmunoGen
$3.58 /

+0.055 (+1.56%)

03/21/22 RBC Capital
ImmunoGen downgraded to Sector Perform from Outperform at RBC Capital
02/10/22 BMO Capital
ImmunoGen initiated with an Outperform at BMO Capital
01/03/22 Guggenheim
ImmunoGen, Merus named 'Best Ideas' in oncology-focused biotech at Guggenheim
12/01/21 Jefferies
ImmunoGen upgraded to Buy at Jefferies after 'best-case data' in PROC
IMGN ImmunoGen
$3.58 /

+0.055 (+1.56%)

  • 02
    Dec
IMGN ImmunoGen
$3.58 /

+0.055 (+1.56%)

Initiation
Johnson & Johnson assumed with an Outperform at SVB Leerink » 06:31
05/23/22
05/23
06:31
05/23/22
06:31
JNJ

Johnson & Johnson

$175.81 /

+2.97 (+1.72%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

05/17/22 BofA
Teva upgraded to Neutral at BofA on potential opioid deal upside
05/17/22 Citi
Johnson & Johnson price target lowered to $205 from $210 at Citi
04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
04/20/22 Credit Suisse
Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

Hot Stocks
Walmart, Symbotic expand partnership » 06:31
05/23/22
05/23
06:31
05/23/22
06:31
WMT

Walmart

$119.05 /

-0.04 (-0.03%)

Symbotic, an A.I.-powered…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WMT Walmart
$119.05 /

-0.04 (-0.03%)

WMT Walmart
$119.05 /

-0.04 (-0.03%)

05/19/22 MKM Partners
Target price target lowered to $180 from $253 at MKM Partners
05/19/22 Truist
Best Buy price target lowered to $83 from $117 at Truist
05/19/22 Stifel
Costco price target lowered to $515 from $565 at Stifel
05/18/22 BMO Capital
Walmart price target lowered to $165 from $170 at BMO Capital
WMT Walmart
$119.05 /

-0.04 (-0.03%)

WMT Walmart
$119.05 /

-0.04 (-0.03%)

WMT Walmart
$119.05 /

-0.04 (-0.03%)

WMT Walmart
$119.05 /

-0.04 (-0.03%)

Recommendations
Baird a buyer into Petco Q1 results as shares offer good value » 06:31
05/23/22
05/23
06:31
05/23/22
06:31
WOOF

Petco

$15.11 /

-1.655 (-9.87%)

Baird analyst Peter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WOOF Petco
$15.11 /

-1.655 (-9.87%)

WOOF Petco
$15.11 /

-1.655 (-9.87%)

05/20/22 Needham
Petco seen as 'safe place to hide' on replenishment demand, says Needham
05/20/22 Jefferies
Pet specialty retail selloff overdone, says Jefferies
05/16/22 Morgan Stanley
Petco initiated with an Equal Weight at Morgan Stanley
05/13/22 Citi
Petco price target lowered to $26 from $28 at Citi
WOOF Petco
$15.11 /

-1.655 (-9.87%)

  • 27
    May
WOOF Petco
$15.11 /

-1.655 (-9.87%)

WOOF Petco
$15.11 /

-1.655 (-9.87%)

Recommendations
Mirum Pharmaceuticals price target raised to $69 from $64 at H.C. Wainwright » 06:30
05/23/22
05/23
06:30
05/23/22
06:30
MIRM

Mirum Pharmaceuticals

$25.67 /

+1.46 (+6.03%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$25.67 /

+1.46 (+6.03%)

03/11/22 Raymond James
Mirum Pharmaceuticals price target raised to $74 from $70 at Raymond James
10/11/21 Piper Sandler
Mirum Pharmaceuticals remains undervalued despite catalysts, says Piper Sandler
09/30/21 H.C. Wainwright
Mirum Pharmaceuticals price target raised to $64 from $51 at H.C. Wainwright
09/30/21 Raymond James
Mirum Pharmaceuticals price target raised to $69 from $51 at Raymond James
MIRM Mirum Pharmaceuticals
$25.67 /

+1.46 (+6.03%)

Initiation
Gilead initiated with a Market Perform at SVB Leerink » 06:29
05/23/22
05/23
06:29
05/23/22
06:29
GILD

Gilead

$63.83 /

+0.55 (+0.87%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GILD Gilead
$63.83 /

+0.55 (+0.87%)

GILD Gilead
$63.83 /

+0.55 (+0.87%)

05/17/22 BMO Capital
Scholar Rock price target lowered to $55 from $74 at BMO Capital
05/16/22 Piper Sandler
Gilead price target lowered to $69 from $73 at Piper Sandler
04/29/22 Piper Sandler
Gilead price target raised to $73 from $72 at Piper Sandler
04/12/22 Piper Sandler
Gilead price target raised to $72 from $71 at Piper Sandler
GILD Gilead
$63.83 /

+0.55 (+0.87%)

GILD Gilead
$63.83 /

+0.55 (+0.87%)

GILD Gilead
$63.83 /

+0.55 (+0.87%)

GILD Gilead
$63.83 /

+0.55 (+0.87%)

Upgrade
Saia upgraded to Buy from Neutral at UBS » 06:29
05/23/22
05/23
06:29
05/23/22
06:29
SAIA

Saia

/

+

UBS analyst Thomas…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAIA Saia
/

+

SAIA Saia
/

+

05/19/22 Citi
Saia price target lowered to $190 from $230 at Citi
05/03/22 Wells Fargo
Saia price target raised to $290 from $273 at Wells Fargo
04/20/22 Raymond James
Saia price target lowered to $275 from $350 at Raymond James
04/08/22 BofA
Saia downgraded to Neutral from Buy at BofA
SAIA Saia
/

+

SAIA Saia
/

+

Recommendations
Boxed price target lowered to $12 from $13 at Citi » 06:28
05/23/22
05/23
06:28
05/23/22
06:28
BOXD

Boxed

$9.31 /

-0.56 (-5.67%)

Citi analyst Ronald Josey…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BOXD Boxed
$9.31 /

-0.56 (-5.67%)

BOXD Boxed
$9.31 /

-0.56 (-5.67%)

04/19/22 Citi
Boxed initiated with a Buy at Citi
01/04/22 BTIG
Boxed initiated with a Neutral at BTIG
01/04/22 BTIG
Boxed initiated with a Neutral at BTIG
11/03/21 DA Davidson
Seven Oaks Acquisition initiated with a Buy at DA Davidson
BOXD Boxed
$9.31 /

-0.56 (-5.67%)

Initiation
Ouster initiated with an Overweight at Cantor Fitzgerald » 06:28
05/23/22
05/23
06:28
05/23/22
06:28
OUST

Ouster

$2.37 /

-0.095 (-3.85%)

Cantor Fitzgerald analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OUST Ouster
$2.37 /

-0.095 (-3.85%)

OUST Ouster
$2.37 /

-0.095 (-3.85%)

03/31/22 Chardan
Ouster initiated with a Buy at Chardan
02/16/22 Citi
Ouster price target lowered to $17 from $19 at Citi
02/08/22 Craig-Hallum
Velodyne stock 60% outperformance 'seems an overreaction,' says Craig-Hallum
01/24/22 Craig-Hallum
Ouster price target lowered to $10 from $20 at Craig-Hallum
OUST Ouster
$2.37 /

-0.095 (-3.85%)

OUST Ouster
$2.37 /

-0.095 (-3.85%)

OUST Ouster
$2.37 /

-0.095 (-3.85%)

Recommendations
Applied Materials price target lowered to $160 from $175 at Citi » 06:27
05/23/22
05/23
06:27
05/23/22
06:27
AMAT

Applied Materials

$106.58 /

-4.23 (-3.82%)

Citi analyst Atif Malik…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMAT Applied Materials
$106.58 /

-4.23 (-3.82%)

AMAT Applied Materials
$106.58 /

-4.23 (-3.82%)

05/20/22 Needham
Applied Materials price target lowered to $130 from $172 at Needham
05/20/22 Craig-Hallum
Applied Materials price target lowered to $145 from $170 at Craig-Hallum
05/20/22 DA Davidson
Applied Materials price target lowered to $170 from $185 at DA Davidson
05/20/22 JPMorgan
Applied Materials price target lowered to $158 from $174 at JPMorgan
AMAT Applied Materials
$106.58 /

-4.23 (-3.82%)

AMAT Applied Materials
$106.58 /

-4.23 (-3.82%)

AMAT Applied Materials
$106.58 /

-4.23 (-3.82%)

AMAT Applied Materials
$106.58 /

-4.23 (-3.82%)

Upgrade
DTE Energy upgraded to Outperform from Neutral at Credit Suisse » 06:27
05/23/22
05/23
06:27
05/23/22
06:27
DTE

DTE Energy

$128.68 /

-0.27 (-0.21%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DTE DTE Energy
$128.68 /

-0.27 (-0.21%)

DTE DTE Energy
$128.68 /

-0.27 (-0.21%)

05/03/22 Citi
DTE Energy price target raised to $146 from $134 at Citi
04/25/22 Credit Suisse
DTE Energy initiated with a Neutral at Credit Suisse
03/11/22 UBS
DTE Energy downgraded to Neutral from Buy at UBS
03/10/22 Argus
DTE Energy price target raised to $132 from $130 at Argus
DTE DTE Energy
$128.68 /

-0.27 (-0.21%)

Recommendations
Alibaba price target lowered to $144 from $160 at Baird » 06:27
05/23/22
05/23
06:27
05/23/22
06:27
BABA

Alibaba

$86.82 /

-0.89 (-1.01%)

Baird analyst Colin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BABA Alibaba
$86.82 /

-0.89 (-1.01%)

BABA Alibaba
$86.82 /

-0.89 (-1.01%)

05/18/22 Truist
Alibaba price target lowered to $132 from $180 at Truist
05/16/22 JPMorgan
Alibaba upgraded to Overweight from Underweight at JPMorgan
05/02/22 Mizuho
Alibaba price target lowered to $160 from $180 at Mizuho
04/11/22 UBS
Alibaba price target lowered to $140 from $150 at UBS
BABA Alibaba
$86.82 /

-0.89 (-1.01%)

BABA Alibaba
$86.82 /

-0.89 (-1.01%)

BABA Alibaba
$86.82 /

-0.89 (-1.01%)

BABA Alibaba
$86.82 /

-0.89 (-1.01%)

Recommendations
Paramount price target lowered to $44 from $47 at Citi » 06:26
05/23/22
05/23
06:26
05/23/22
06:26
PARA

Paramount

$32.66 /

+0.43 (+1.33%)

Citi analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PARA Paramount
$32.66 /

+0.43 (+1.33%)

PARA Paramount
$32.66 /

+0.43 (+1.33%)

05/04/22 Deutsche Bank
Paramount price target lowered to $43 from $45 at Deutsche Bank
04/19/22 Rosenblatt
Paramount initiated with a Sell at Rosenblatt
04/14/22 Deutsche Bank
Paramount price target raised to $45 from $43 at Deutsche Bank
04/01/22 JPMorgan
Paramount reinstated with a Neutral at JPMorgan
PARA Paramount
$32.66 /

+0.43 (+1.33%)

PARA Paramount
$32.66 /

+0.43 (+1.33%)

PARA Paramount
$32.66 /

+0.43 (+1.33%)

PARA Paramount
$32.66 /

+0.43 (+1.33%)

Initiation
Horizon Therapeutics initiated with a Market Perform at SVB Leerink » 06:26
05/23/22
05/23
06:26
05/23/22
06:26
HZNP

Horizon Therapeutics

$90.33 /

+0.96 (+1.07%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$90.33 /

+0.96 (+1.07%)

HZNP Horizon Therapeutics
$90.33 /

+0.96 (+1.07%)

03/14/22 Oppenheimer
Horizon Therapeutics initiated with an Outperform at Oppenheimer
01/26/22 Piper Sandler
Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
01/18/22 JPMorgan
Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
12/08/21
Fly Intel: Top five analyst initiations
HZNP Horizon Therapeutics
$90.33 /

+0.96 (+1.07%)

HZNP Horizon Therapeutics
$90.33 /

+0.96 (+1.07%)

Upgrade
Consolidated Edison upgraded to Neutral from Sell at Guggenheim » 06:26
05/23/22
05/23
06:26
05/23/22
06:26
ED

Consolidated Edison

$95.81 /

+0.905 (+0.95%)

Guggenheim analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ED Consolidated Edison
$95.81 /

+0.905 (+0.95%)

ED Consolidated Edison
$95.81 /

+0.905 (+0.95%)

05/03/22 Wells Fargo
Wells Fargo downgrades Consolidated Edison to sell on 'tricky' NY rate case
05/02/22 Wells Fargo
Consolidated Edison downgraded to Underweight from Equal Weight at Wells Fargo
04/25/22 Credit Suisse
Consolidated Edison initiated with a Neutral at Credit Suisse
03/10/22 Mizuho
Consolidated Edison price target raised to $94 from $90 at Mizuho
ED Consolidated Edison
$95.81 /

+0.905 (+0.95%)

  • 16
    Jun
Recommendations
Dell Technologies price target lowered to $65 from $70 at Citi » 06:25
05/23/22
05/23
06:25
05/23/22
06:25
DELL

Dell Technologies

$40.05 /

-1 (-2.44%)

Citi analyst Jim Suva…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DELL Dell Technologies
$40.05 /

-1 (-2.44%)

DELL Dell Technologies
$40.05 /

-1 (-2.44%)

04/19/22 KGI Securities
Dell Technologies initiated with a Neutral at KGI Securities
04/01/22 Goldman Sachs
Dell Technologies downgraded to Neutral from Conviction Buy at Goldman Sachs
03/31/22 Barclays
Dell Technologies price target lowered to $53 from $54 at Barclays
03/31/22 Morgan Stanley
Dell Technologies downgraded to Equal Weight from Overweight at Morgan Stanley
DELL Dell Technologies
$40.05 /

-1 (-2.44%)

DELL Dell Technologies
$40.05 /

-1 (-2.44%)

DELL Dell Technologies
$40.05 /

-1 (-2.44%)

DELL Dell Technologies
$40.05 /

-1 (-2.44%)

Recommendations
Marvell price target lowered to $80 from $95 at UBS » 06:24
05/23/22
05/23
06:24
05/23/22
06:24
MRVL

Marvell

$54.13 /

-0.18 (-0.33%)

UBS analyst Timothy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$54.13 /

-0.18 (-0.33%)

MRVL Marvell
$54.13 /

-0.18 (-0.33%)

05/20/22 Oppenheimer
Marvell price target lowered to $90 from $110 at Oppenheimer
05/17/22 Piper Sandler
Piper moves to 'more positive stance' on semiconductor stocks
04/25/22 Raymond James
Marvell upgraded to Outperform from Market Perform at Raymond James
04/25/22 Raymond James
Marvell upgraded to Outperform from Market Perform at Raymond James
MRVL Marvell
$54.13 /

-0.18 (-0.33%)

MRVL Marvell
$54.13 /

-0.18 (-0.33%)

MRVL Marvell
$54.13 /

-0.18 (-0.33%)

Recommendations
Foot Locker price target raised to $32 from $30 » 06:24
05/23/22
05/23
06:24
05/23/22
06:24
FL

Foot Locker

$31.52 /

+1.22 (+4.03%)

Baird analyst Jonathan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FL Foot Locker
$31.52 /

+1.22 (+4.03%)

FL Foot Locker
$31.52 /

+1.22 (+4.03%)

05/16/22 Deutsche Bank
Foot Locker price target lowered to $30 from $32 at Deutsche Bank
05/16/22 OTR Global
Foot Locker downgraded to Mixed from Positive at OTR Global
03/28/22 Cowen
Cowen cuts Foot Locker to Market Perform, more cautious following March data
03/28/22 Cowen
Foot Locker downgraded to Market Perform from Outperform at Cowen
FL Foot Locker
$31.52 /

+1.22 (+4.03%)

FL Foot Locker
$31.52 /

+1.22 (+4.03%)

FL Foot Locker
$31.52 /

+1.22 (+4.03%)

FL Foot Locker
$31.52 /

+1.22 (+4.03%)

Initiation
AbbVie initiated with an Underperform at SVB Leerink » 06:23
05/23/22
05/23
06:23
05/23/22
06:23
ABBV

AbbVie

$151.04 /

-0.8 (-0.53%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

05/13/22 Piper Sandler
Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler
05/06/22 Daiwa
AbbVie downgraded to Neutral from Outperform at Daiwa
05/03/22 Morgan Stanley
Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure
05/02/22 Morgan Stanley
AbbVie's recent weakness a buying opportunity, says Morgan Stanley
ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

ABBV AbbVie
$151.04 /

-0.8 (-0.53%)

Recommendations
Stealth Biotherapeutics price target lowered to $1.50 from $4 at H.C. Wainwright » 06:22
05/23/22
05/23
06:22
05/23/22
06:22
MITO

Stealth Biotherapeutics

/

+

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MITO Stealth Biotherapeutics
/

+

MITO Stealth Biotherapeutics
/

+

07/01/21 Maxim
Stealth Biotherapeutics initiated with a Buy at Maxim
07/01/21 Maxim
Stealth Biotherapeutics initiated with a Buy at Maxim
Recommendations
Zymeworks price target lowered to $40 from $44 at H.C. Wainwright » 06:21
05/23/22
05/23
06:21
05/23/22
06:21
ZYME

Zymeworks

$5.99 /

+0.155 (+2.66%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZYME Zymeworks
$5.99 /

+0.155 (+2.66%)

ZYME Zymeworks
$5.99 /

+0.155 (+2.66%)

05/09/22 Citi
Zymeworks should reject 'opportunistic' $10.50 per share offer, says Citi
05/05/22 Guggenheim
Zymeworks upgraded to Buy at Guggenheim amid low expectations
05/05/22 Guggenheim
Zymeworks upgraded to Buy from Neutral at Guggenheim
03/15/22 Evercore ISI
Zymeworks initiated with an Outperform at Evercore ISI
ZYME Zymeworks
$5.99 /

+0.155 (+2.66%)

  • 27
    Jan
ZYME Zymeworks
$5.99 /

+0.155 (+2.66%)

Recommendations
Atara Biotherapeutics price target lowered to $29 from $31 at H.C. Wainwright » 06:20
05/23/22
05/23
06:20
05/23/22
06:20
ATRA

Atara Biotherapeutics

$5.17 /

+0.015 (+0.29%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ATRA Atara Biotherapeutics
$5.17 /

+0.015 (+0.29%)

ATRA Atara Biotherapeutics
$5.17 /

+0.015 (+0.29%)

05/09/22 Citi
Citi downgrades Atara Biotherapeutics on lack of near-term drivers
05/09/22 Citi
Atara Biotherapeutics downgraded to Neutral from Buy at Citi
03/28/22 JPMorgan
Atara Biotherapeutics price target lowered to $22 from $27 at JPMorgan
03/08/22 Mizuho
Atara Biotherapeutics price target lowered to $39 from $41 at Mizuho
ATRA Atara Biotherapeutics
$5.17 /

+0.015 (+0.29%)

Recommendations
Snowflake price target lowered to $180 from $260 at UBS » 06:20
05/23/22
05/23
06:20
05/23/22
06:20
SNOW

Snowflake

$141.51 /

-5.36 (-3.65%)

UBS analyst Karl…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

05/20/22 Barclays
Snowflake price target lowered to $218 from $313 at Barclays
05/18/22 Mizuho
Snowflake price target lowered to $225 from $370 at Mizuho
05/10/22 Truist
Snowflake price target lowered to $300 from $350 at Truist
04/25/22 Wolfe Research
Snowflake initiated with an Outperform at Wolfe Research
SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

SNOW Snowflake
$141.51 /

-5.36 (-3.65%)

Initiation
Amgen initiated with a Market Perform at SVB Leerink » 06:20
05/23/22
05/23
06:20
05/23/22
06:20
AMGN

Amgen

/

+

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMGN Amgen
/

+

AMGN Amgen
/

+

05/10/22 Mizuho
Amgen price target raised to $208 from $202 at Mizuho
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
04/28/22 BMO Capital
Amgen price target lowered to $243 from $263 at BMO Capital
04/28/22 Piper Sandler
Amgen price target raised to $260 from $255 at Piper Sandler
AMGN Amgen
/

+

AMGN Amgen
/

+

AMGN Amgen
/

+

AMGN Amgen
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.